Journal
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 53, Issue 11, Pages 1799-1805Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2015-0079
Keywords
fibrosis; microvascular abnormalities; pulmonary fibrosis; soluble urokinase plasminogen activator receptor; systemic sclerosis
Categories
Funding
- Hungarian Scientific Research Fund (OTKA) [101661]
- research grant of Hungarian Association of Rheumatologist
- Zoltan Magyary Scholarship [TAMOP-4.2.4. A/2-11-1-2012-001]
Ask authors/readers for more resources
Background: Urokinase plasminogen activator receptor (uPAR) is a key component of the fibrinolytic system involved in extracellular matrix remodeling and angiogenesis. Novel animal models supported the key role of uPAR not only in fibrosis but also in systemic sclerosis (SSc)-related microvascular abnormalities. The aim of this study was to investigate plasma soluble uPAR (suPAR) levels in SSc, and their association with organ-specific involvement. Methods: suPAR concentrations were measured by ELISA in SSc patient (n=83) and in healthy controls (n=29). Simultaneously, CRP and ESR were assessed. Detailed clinical data including skin, lung, heart and microvascular characteristics were evaluated at sampling. Results: suPAR values were higher in SSc patients than in controls. Subgroup analysis showed higher suPAR values in diffuse cutaneous-than in limited cutaneous SSc and correlated with anti-Scl-70+. suPAR levels also associated with pulmonary function test parameters of fibrosis, presence of microvascular lesions (e.g., Raynaud phenomenon, naifold capillaroscopic abnormalities and digital ulcers) and arthritis. Conclusions: Our data indicate that suPAR might be a valuable early diagnostic marker of SSc which also correlates with disease severity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available